Prevalence of Mast Cell Activation Disorders and Hereditary Alpha Tryptasemia Amongst POTS and EDS Patients: A Systematic Review
Abstract
BACKGROUND
Postural Orthostatic Tachycardia Syndrome (POTS) and Ehlers-Danlos Syndrome (EDS) are often reported to occur concurrently with Mast Cell Activation Disorders (MCADs) and Hereditary Alpha Tryptasemia (HAT). However, it remains unclear whether evidence supporting this relationship exists.
OBJECTIVE
To determine the prevalence of MCADs and HAT in patients diagnosed with EDS and or POTS.
METHODS
We conducted a systematic search of MEDLINE (OVID), EMBASE (OVID), Scopus, and Web of Science with the assistance of an experienced medical librarian. We focused on patients with any MCAD or HAT in conjunction with a diagnosis of POTS and/or EDS.
RESULTS
A total of 200 records were screened, 107 were excluded based on the title or abstract, 92 full texts were reviewed, and one record was not retrieved. No studies were identified that met our primary criterion of including patients diagnosed with any MCAD or HAT alongside POTS and/or EDS based on our pre-specified diagnostic criteria.
CONCLUSION
Our review did not find evidence to confirm a relationship between MCADs, HAT, POTS, and EDS. However, it must be mentioned that one study showed an association between MCAS, POTS, and EDS and came close to meeting the full diagnostic criteria for MCAS, unlike other studies. This indicates that further research using strict and validated diagnostic criteria is needed to clarify whether a true association between conditions exists.
How strong is the evidence?
Evidence Hub reads this as a systematic review, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.